ULTRAGENYX PHARMACEUTICAL INC. Operating Expenses
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Operating Expenses of $169.75 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-08-03
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for the quarter ending 2021-06-30 was $169.75M, a 36.06% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for the quarter ending 2021-03-31 was $205.96M, a 31.21% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for the quarter ending 2020-12-31 was $187.62M, a 44.28% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for the quarter ending 2020-09-30 was $131.78M, a 8.38% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for fiscal 2020 was $601.15M, a 13.88% increase from fiscal 2019.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for fiscal 2019 was $527.89M, a 24.83% increase from fiscal 2018.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for fiscal 2018 was $422.87M, a 27.54% increase from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. operating expenses for fiscal 2017 was $331.55M, a 33.62% increase from fiscal 2016.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 47 month |
|---|---|---|---|---|---|
| 2021-06-30 | $169.75M 10-Q · filed 2021-08-03 | $375.71M 10-Q · filed 2021-08-03 | $563.34M derived: sum of 3 quarters · filed 2021-08-03 | $695.12M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2021-03-31 | $205.96M 10-Q · filed 2021-05-05 | $393.59M derived: sum of 2 quarters · filed 2021-05-05 | $525.37M derived: sum of 3 quarters · filed 2021-05-05 | $650.14M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-12-31 | $187.62M 10-K · filed 2021-02-12 | $319.41M derived: sum of 2 quarters · filed 2021-02-12 | $444.17M derived: sum of 3 quarters · filed 2021-08-03 | $601.15M 10-K · filed 2021-02-12 | |
| 2020-09-30 | $131.78M 10-K · filed 2021-02-12 | $256.55M derived: sum of 2 quarters · filed 2021-08-03 | $413.52M 10-Q · filed 2020-10-27 | $543.57M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-06-30 | $124.76M 10-Q · filed 2021-08-03 | $281.74M 10-Q · filed 2021-08-03 | $411.78M derived: sum of 3 quarters · filed 2021-08-03 | $555.62M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-03-31 | $156.97M 10-Q · filed 2021-05-05 | $287.02M derived: sum of 2 quarters · filed 2021-05-05 | $430.85M derived: sum of 3 quarters · filed 2021-05-05 | $567.48M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | $130.04M 10-K · filed 2021-02-12 | $273.88M derived: sum of 2 quarters · filed 2021-02-12 | $410.50M derived: sum of 3 quarters · filed 2021-02-12 | $527.89M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $143.83M 10-K · filed 2021-02-12 | $280.46M derived: sum of 2 quarters · filed 2021-02-12 | $397.84M 10-Q · filed 2020-10-27 | $504.44M derived: sum of 4 quarters · filed 2021-02-12 | |
| 2019-06-30 | $136.62M 10-K · filed 2021-02-12 | $254.01M 10-Q · filed 2020-07-30 | $360.61M derived: sum of 3 quarters · filed 2021-02-12 | $462.02M derived: sum of 4 quarters · filed 2021-02-12 | |
| 2019-03-31 | $117.39M 10-K · filed 2021-02-12 | $223.99M derived: sum of 2 quarters · filed 2021-02-12 | $325.40M derived: sum of 3 quarters · filed 2021-02-12 | $433.09M derived: sum of 4 quarters · filed 2021-02-12 | |
| 2018-12-31 | $106.60M 10-K · filed 2020-02-14 | $208.01M derived: sum of 2 quarters · filed 2020-02-14 | $315.70M derived: sum of 3 quarters · filed 2020-02-14 | $422.87M 10-K · filed 2021-02-12 | |
| 2018-09-30 | $101.41M 10-K · filed 2020-02-14 | $209.10M derived: sum of 2 quarters · filed 2020-02-14 | $316.27M 10-Q · filed 2019-11-06 | $415.51M derived: sum of 4 quarters · filed 2020-02-14 | |
| 2018-06-30 | $107.69M 10-K · filed 2020-02-14 | $214.86M 10-Q · filed 2019-08-02 | $314.11M derived: sum of 3 quarters · filed 2020-02-14 | $398.02M derived: sum of 4 quarters · filed 2020-02-14 | |
| 2018-03-31 | $107.16M 10-K · filed 2020-02-14 | $206.41M derived: sum of 2 quarters · filed 2020-02-14 | $290.32M derived: sum of 3 quarters · filed 2020-02-14 | $368.76M derived: sum of 4 quarters · filed 2020-02-14 | |
| 2017-12-31 | $99.25M 10-K · filed 2019-02-20 | $183.16M derived: sum of 2 quarters · filed 2019-02-20 | $261.60M derived: sum of 3 quarters · filed 2019-02-20 | $331.55M 10-K · filed 2020-02-14 | |
| 2017-09-30 | $83.91M 10-K · filed 2019-02-20 | $162.35M derived: sum of 2 quarters · filed 2019-02-20 | $232.31M 10-Q · filed 2018-11-06 | $302.86M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-06-30 | $78.44M 10-K · filed 2019-02-20 | $148.40M 10-Q · filed 2018-08-03 | $218.95M derived: sum of 3 quarters · filed 2019-02-20 | $284.84M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-03-31 | $69.95M 10-K · filed 2019-02-20 | $140.51M derived: sum of 2 quarters · filed 2019-02-20 | $206.40M derived: sum of 3 quarters · filed 2019-02-20 | $264.47M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2016-12-31 | $70.55M 10-K · filed 2018-02-21 | $136.45M derived: sum of 2 quarters · filed 2018-02-21 | $194.52M derived: sum of 3 quarters · filed 2018-02-21 | $248.14M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $65.89M 10-K · filed 2018-02-21 | $123.96M derived: sum of 2 quarters · filed 2018-02-21 | $177.59M 10-Q · filed 2017-11-03 | $233.74M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $58.07M 10-K · filed 2018-02-21 | $111.69M 10-Q · filed 2017-07-28 | $167.85M derived: sum of 3 quarters · filed 2018-02-21 | $207.79M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | $53.62M 10-K · filed 2018-02-21 | $109.78M derived: sum of 2 quarters · filed 2018-02-21 | $149.72M derived: sum of 3 quarters · filed 2018-02-21 | $179.86M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | $56.16M 10-K · filed 2017-02-17 | $96.09M derived: sum of 2 quarters · filed 2017-02-17 | $126.24M derived: sum of 3 quarters · filed 2017-02-17 | $147.74M 10-K · filed 2018-02-21 | |
| 2015-09-30 | $39.94M 10-K · filed 2017-02-17 | $70.08M derived: sum of 2 quarters · filed 2017-02-17 | $91.58M 10-Q · filed 2016-11-08 | $108.52M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $30.14M 10-K · filed 2017-02-17 | $51.64M 10-Q · filed 2016-08-09 | $68.59M derived: sum of 3 quarters · filed 2017-02-17 | $84.42M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $21.50M 10-K · filed 2017-02-17 | $38.45M derived: sum of 2 quarters · filed 2017-02-17 | $54.28M derived: sum of 3 quarters · filed 2017-02-17 | $67.94M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $16.94M 10-K · filed 2016-02-26 | $32.78M derived: sum of 2 quarters · filed 2016-02-26 | $46.44M derived: sum of 3 quarters · filed 2016-02-26 | $56.78M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $15.84M 10-K · filed 2016-02-26 | $29.50M derived: sum of 2 quarters · filed 2016-02-26 | $39.84M 10-Q · filed 2015-11-10 | $49.36M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $13.66M 10-K · filed 2016-02-26 | $24.00M 10-Q · filed 2015-08-14 | $33.52M derived: sum of 3 quarters · filed 2016-02-26 | $41.29M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $10.34M 10-K · filed 2016-02-26 | $19.86M derived: sum of 2 quarters · filed 2016-02-26 | $27.63M derived: sum of 3 quarters · filed 2016-02-26 | $35.87M derived: sum of 4 quarters · filed 2016-02-26 | $66.42M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $9.53M 10-K · filed 2015-03-27 | $17.29M derived: sum of 2 quarters · filed 2015-03-27 | $25.53M derived: sum of 3 quarters · filed 2015-03-27 | $32.28M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $7.76M 10-K · filed 2015-03-27 | $16.01M derived: sum of 2 quarters · filed 2015-03-27 | $22.75M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $8.25M 10-K · filed 2015-03-27 | $14.99M 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $6.75M 10-K · filed 2015-03-27 | ||||
| 2012-12-31 | $15.98M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |